Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

18F-FDG PET/CT Monitoring of Tumor Response to Tyrosine Kinase Inhibitors and Alkylating Drugs in an SDH-Deficient GIST.

Clinical nuclear medicine - 1 Oct 2021

Somme François, Bender Laura, Kurtz Jean-Emmanuel, Gantzer Justine, Imperiale Alessio

Abstract excerpt

ABSTRACT: Succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GISTs) are associated with loss of function of SDH complex and represent 5% to 7.5% of GISTs. SDH-deficient GISTs usually develop in the stomach of children and young adults, and could be part of Carney triad or Carney-Stratakis syndromes including paraganglioma. SDH-deficient GISTs are often indolent despite the high rate of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkylating Agents
Share to Fluorodeoxyglucose F18

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Pharmaceutical Preparations

Share to Positron Emission Tomography Computed Tomography

Share to Protein Kinase Inhibitors

Share to Succinate Dehydrogenase

Share to Young Adult

Source

Identifiers

PMID: 33782316
DOI: 10.1097/RLU.0000000000003615

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

18F-FDG PET/CT Monitoring of Tumor Response to Tyrosine Kinase Inhibitors and Alkylating Drugs in an SDH-Deficient GIST.PMID 33782316Read ↗

Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors.Semantic proximity Read ↗

Succinate Dehydrogenase-Deficient GISTsSemantic proximity Read ↗

Succinate dehydrogenase-deficient gastrointestinal stromal tumorsSemantic proximity Read ↗

Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review.Semantic proximity Read ↗

Succinate Dehydrogenase Subunit B (SDHB) Is Expressed in Neurofibromatosis 1-Associated Gastrointestinal Stromal Tumors (Gists): Implications for the SDHB Expression Based Classification of GistsSemantic proximity Read ↗

Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors.Semantic proximity Read ↗

A Review of Genomic Testing and SDH ‐ Deficiency in Gastrointestinal Stromal Tumors: Getting to the GISTSemantic proximity Read ↗

Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumorsSemantic proximity Read ↗

Loss of SDHA Expression Identifies SDHA Mutations in Succinate Dehydrogenase–deficient Gastrointestinal Stromal TumorsSemantic proximity Read ↗

Conventional Risk Stratification Fails to Predict Progression of Succinate Dehydrogenase-deficient Gastrointestinal Stromal Tumors: A Clinicopathologic Study of 76 Cases.Semantic proximity Read ↗

Succinate dehydrogenase (SDH)‐deficient neoplasiaSemantic proximity Read ↗

Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.